Patent · US Active

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

US10597439B2 · kind B2 · utility

3Cited by

52References

7Claims

0Family size

Assignee

MedImmune Limited · US

Inventors

Antonio Digiandomenico · Gaithersburg, US
Paul Warrener · Seattle, US
Charles K. Stover · Gaithersburg, US
Bret Sellman · Rochester, US
Ralph Minter · Cambridge, GB
Sandrine Guillard · Cambridge, GB
Steven Rust · Cambridge, GB
Mladen Tomich · New York, US
Vignesh Venkatraman · Cambridge, GB
Reena Varkey · Gaithersburg, US
Li Peng · Gaithersburg, US
Melissa Damschroder · Gaithersburg, US
Partha S. Chowdhury · Gaithersburg, US
Nazzareno Dimasi · Gaithersburg, US
Ryan Fleming · Gaithersburg, US
Binyam Bezabeh · Gaithersburg, US
Changshou Gao · Potomac, US
Godfrey Jonah Anderson Rainey · Gaithersburg, US
Cuihua Gao · Gaithersburg, US

Key dates

Filing date	Nov 6, 2012
Grant date	Mar 24, 2020
Priority date	—
Expiry date	Feb 21, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.